Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jounce

Bristol-Myers Squibb (BMS) building

Opdivo gets EU lung cancer nod as kidney cancer trial is halted

Bristol-MyersSquibb's checkpoint inhibitor gains European license for lung cancer

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

Celgene building

Celgene and Juno announce ten-year cancer deal

The firms’ pact will focus on the new area of immunotherapy

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

Novel anticoagulant antidotes prove their worth

Reversal agents from Portola and BMS and Boehringer shine in late-stage clinical trials

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo wins anti-PD1 race in Europe

Treatment given the EMA nod of approval for melanoma

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

Bristol-Myers Squibb (BMS) building

BMS melanoma combo impresses at ASCO

Increases survival in difficult to treat form of skin cancer

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

- PMLiVE

Michael Zaiac moves from GSK to Celgene

He takes up the role of VP, medical affairs, haematology-oncology EMEA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links